Compare Neurocrine Biosciences Inc (NBIX) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Zoom Video Communications, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Zoom Video Communications, Inc. trades at $96.82 (market cap $28.14B). The key difference: Zoom Video Communications, Inc. is the larger of the two by market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | ZM | |
|---|---|---|
Market Cap | $15.77B | $28.14B |
Sector | Health | Technology |
52-Week High | $185.50 | $111.88 |
52-Week Low | $123.10 | $72.72 |
Enterprise Value | $15.78B | $20.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Zoom (ZM) trades at $96.44, down 4.83% on the day, amid a bearish technical signal and soft Q3 profit guidance that overshadowed a Q2 earnings beat. The stock shows strong fundamentals with a P/E of 8.95, net income margin of 65.19%, and positive cash flow trends, but faces near-term pressure from investor concerns over growth outlook. Recent board appointments and enterprise revenue strength provide some optimism.
The outlook is mixed; solid profitability and low valuation offer upside potential toward the $119.63 consensus price target, but risks include competitive pressures and execution on guidance. Analyst sentiment is cautious with 55.1% hold ratings, reflecting uncertainty around future growth catalysts versus current operational resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
